180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reiterated at Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

180 Life Sciences Stock Performance

Shares of NASDAQ ATNF traded down $0.02 during trading hours on Friday, reaching $1.56. 85,595 shares of the stock traded hands, compared to its average volume of 1,006,117. The company’s 50-day simple moving average is $2.10 and its two-hundred day simple moving average is $2.24. 180 Life Sciences has a 52-week low of $1.16 and a 52-week high of $17.75.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.